Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07368478) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies' on Jan. 12.

Brief Summary: This is a phase Ia/Ib, open-label, dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, and preliminary anticancer activity of BC2027 in patients with advanced solid Malignanciesr

Study Start Date: Nov. 24, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Malignancies

Intervention: DRUG: BC2027 for Injection

Drug: BC2027 for Injection (lyophilized powder, 20 mg/vial) Administration: Administered via intra...